A Phase 3 interventional study of Niacin ER/Simvastatin Tablets and atorvastatin in Hyperlipidemia and Mixed Dyslipidemia, sponsored by Abbott. Completed at 46 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2011-06-13.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing simvastatin in Hyperlipidemias — 1 open to participants now, 1 under way, none of them phase 3. Simvastatin · Hyperlipidemias.
Among the 14 studies testing simvastatin in Hyperlipidemias, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 9 in phase 3, and was the 9th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →1 of the 14 studies testing simvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:
National University Hospital, Singapore · Sites in Singapore
Ages 21+
By country, each count listing its studies:
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 10 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 516 across the 13 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 6 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing simvastatin in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are currently off lipid-modifying therapy. This was a prospective, randomized, open-label, blinded endpoint (PROBE) study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following laboratory criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niacin ER/Simvastatin Tablets
Drug: atorvastatin
Drug pages: Niacin · Simvastatin
Up to 2000 mg/40 mg at bedtime
Also known as: ABT-919/483, Niacin ER/Simvastatin, Simcor
40 mg at bedtime
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12
(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C
Time frame: From baseline to Week 12
Percent Change in HDL-C From Baseline to Week 8
(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C
Time frame: From baseline to Week 8
Percent Change in Non-HDL-C From Baseline to Week 8
(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C
Time frame: From baseline to Week 8
Percent Change in Non-HDL-C From Baseline to Week 12
(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C
Time frame: From baseline to Week 12
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12
(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C
Time frame: From baseline to Week 12
Percent Change in Triglycerides From Baseline to Week 12
(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides
Time frame: From baseline to Week 12
Percent Change in LDL-C:HDL-C Ratio
(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio
Time frame: From baseline to Week 12
Percent Change in Total Cholesterol From Baseline to Week 12
(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol
Time frame: From baseline to Week 12
Percent Change in Total Cholesterol:HDL-C Ratio
(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio
Time frame: From baseline to Week 12
Percent Change in Lipoprotein A From Baseline to Week 12
(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A
Time frame: From baseline to Week 12
Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12
Time frame: 12 weeks
Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12
For high-risk patients (coronary heart disease or equivalent), LDL-C \< 100 mg/dL and non-HDL-C \< 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C \< 130 mg/dL and non-HDL-C \< 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C \< 160 mg/dL and non-HDL-C \< 190 mg/dL.
Time frame: 12 weeks
Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12
Time frame: 12 weeks
Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12
NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C \< 100 mg/dL; for moderate risk patients, LDL-C \< 130 mg/dL; for low-risk patients: LDL-C \< 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.
Time frame: 12 weeks
| Milestone | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Started | 114 | 79 |
| Completed | 82 | 70 |
| Not completed | 32 | 9 |
(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12 | 30.1 (25.6 to 34.6) | 9.4 (4.3 to 14.4) |
(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in HDL-C From Baseline to Week 8 | 26.7 (23.1 to 30.2) | 1.4 (-2.7 to 5.4) |
(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Week 8 | -45.0 (-48.9 to -41.0) | -44.3 (-48.8 to -39.8) |
(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Week 12 | -43.4 (-47.7 to -39.0) | -43.3 (-48.2 to -38.5) |
(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 | -43.8 (-48.3 to -39.2) | -46.0 (-51.0 to -40.9) |
(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Triglycerides From Baseline to Week 12 | -44.0 (-62.8 to -20.9) | -37.0 (-47.8 to -18.8) |
(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in LDL-C:HDL-C Ratio | -54.5 (-59.1 to -49.8) | -50.5 (-55.7 to -45.3) |
(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Week 12 | -31.3 (-34.8 to -27.7) | -35.1 (-39.1 to -31.1) |
(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Total Cholesterol:HDL-C Ratio | -45.2 (-49.0 to -41.3) | -40.3 (-44.7 to -36.0) |
(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A
| percent change | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percent Change in Lipoprotein A From Baseline to Week 12 | -15.8 (-36.8 to 8.8) | 16.0 (-7.1 to 30.8) |
| Percentage of subjects | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12 | 78 | 28 |
For high-risk patients (coronary heart disease or equivalent), LDL-C \< 100 mg/dL and non-HDL-C \< 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C \< 130 mg/dL and non-HDL-C \< 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C \< 160 mg/dL and non-HDL-C \< 190 mg/dL.
| Percentage of subjects | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12 | 78 | 84 |
| Percentage of subjects | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12 | 79 | 70 |
NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C \< 100 mg/dL; for moderate risk patients, LDL-C \< 130 mg/dL; for low-risk patients: LDL-C \< 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.
| Percentage of subjects | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12 | 65 | 34 |
Non-serious events are listed at a 2.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niacin Extended-release Plus Simvastatin | — | — | — |
| Atorvastatin | — | — | — |
| Event | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| Chest painGeneral disorders | 1/114 | 1/79 |
| Coronary artery diseaseCardiac disorders | 1/114 | 0/79 |
| Event | Niacin Extended-release Plus Simvastatin | Atorvastatin |
|---|---|---|
| FlushingVascular disorders | 77/114 | 8/79 |
| VomitingGastrointestinal disorders | 11/114 | 0/79 |
| DiarrheaGastrointestinal disorders | 9/114 | 2/79 |
| NauseaGastrointestinal disorders | 9/114 | 0/79 |
| HeadacheNervous system disorders | 9/114 | 2/79 |
| PruritusSkin and subcutaneous tissue disorders | 7/114 | 0/79 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/114 | 4/79 |
| ConstipationGastrointestinal disorders | 5/114 | 0/79 |
| Tooth infectionInfections and infestations | 3/114 | 0/79 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/114 | 1/79 |
| Age, Categorical(Participants) | Niacin Extended-release Plus Simvastatin | Atorvastatin | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 93 | 73 | 166 |
| >=65 years | 21 | 6 | 27 |
| Age Continuous(years) | Niacin Extended-release Plus Simvastatin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 55.1 ± 12.06 | 51.5 ± 11.12 | 53.6 ± 11.80 |
| Sex: Female, Male(Participants) | Niacin Extended-release Plus Simvastatin | Atorvastatin | Total |
|---|---|---|---|
| Female | 71 | 38 | 109 |
| Male | 43 | 41 | 84 |
| Region of Enrollment(participants) | Niacin Extended-release Plus Simvastatin | Atorvastatin | Total |
|---|---|---|---|
| United States | 114 | 79 | 193 |
The record gives a start of Apr 2007 and a primary completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niacin · Simvastatin · Atorvastatin